Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.

Among RGD-dependent integrins, the avb3 receptor has recently received increasing attention as a therapeutic target because of its critical role in tumor-induced angiogenesis and metastasis formation. Here, we describe a new peptide antagonist of Rvâ3 receptor, designed on the basis of the crystal structure of integrin avb3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. Cell adhesion assays have demonstrated that the peptide is a potent and selective antagonist of the avb3 receptor.